Susana Vives

2.2k total citations · 1 hit paper
37 papers, 791 citations indexed

About

Susana Vives is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Susana Vives has authored 37 papers receiving a total of 791 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hematology, 13 papers in Oncology and 10 papers in Genetics. Recurrent topics in Susana Vives's work include Acute Myeloid Leukemia Research (21 papers), Hematopoietic Stem Cell Transplantation (9 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Susana Vives is often cited by papers focused on Acute Myeloid Leukemia Research (21 papers), Hematopoietic Stem Cell Transplantation (9 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Susana Vives collaborates with scholars based in Spain, France and Italy. Susana Vives's co-authors include Josep‐María Ribera, Pau Montesinos, Michael Heuser, Giambattista Bertani, Diego A. Gianolio, Jianan Hui, Hartmut Döhner, Christian Récher, Shuchi S. Pandya and Jianxiang Wang and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Susana Vives

32 papers receiving 781 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia

2022 295 citations Pau Montesinos, Christian Récher et al. profile →

Peers

Countries citing papers authored by Susana Vives

Since Specialization

Citations

This map shows the geographic impact of Susana Vives's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susana Vives with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susana Vives more than expected).

Fields of papers citing papers by Susana Vives

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susana Vives. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susana Vives. The network helps show where Susana Vives may publish in the future.

Co-authorship network of co-authors of Susana Vives

This figure shows the co-authorship network connecting the top 25 collaborators of Susana Vives. A scholar is included among the top collaborators of Susana Vives based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susana Vives. Susana Vives is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated cases 2025 ·Diagnostic Pathology ·(unknown), (unknown), (unknown), Núria González, Francesca Guijarro, (unknown), Marta Pratcorona, Ignasi Gich, (unknown), Júlia Perera‐Bel, Lurdes Zamora, (unknown), Antònia Sampol, Antoni García‐Guiñón, Susana Vives, Mar Tormo, Montserrat Arnán, Neus Villamor, Josep Nomdedéu	0
2	ALIDHE phase 3b study design: ivosidenib + azacitidine in adults with newly diagnosed IDH1 mutant acute myeloid leukemia 2025 ·Future Oncology ·Paresh Vyas, Sam Salek, Susana Vives, Christian Récher, Hartmut Döhner, Adriano Venditti, (unknown), (unknown), (unknown), Jana Pelouchová, Robert K. Hills, (unknown)	1
3	Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed IDH1 mutant AML 2025 ·Future Oncology ·(unknown), Jana Pelouchová, Robert K. Hills, Sam Salek, (unknown), (unknown), (unknown), Susana Vives, Christian Récher, Hartmut Döhner, Adriano Venditti, Paresh Vyas	1
4	Identification of novel NUP98 fusion partners and comutations in acute myeloid leukemia: an adult cohort study 2024 ·Blood Advances ·(unknown), (unknown), (unknown), Neus Ruiz‐Xivillé, (unknown), Lurdes Zamora, Susana Vives, Rosa Coll, Clara Maluquer, Isabel Granada, Françesc Solé, Manel Esteller, María Berdasco	6
5	Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia 2024 ·Blood Advances ·Esperanza Martín‐Sánchez, Laura Blanco, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi van de Velde, Tomáš Jelı́nek, (unknown), Felipe Prósper, Jesús F. San Miguel, Ana Alfonso Piérola, Juan Bergua, Rebeca Rodríguez‐Veiga, Susana Vives, David Martínez‐Cuadrón, Pau Montesinos, Bruno Paiva, Aintzane Zabaleta	5
6	Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort 2023 ·Blood Cancer Journal ·(unknown), Marta Pratcorona, Ana Garrido, (unknown), Álex Bataller, Mar Tormo, Montserrat Arnán, Susana Vives, Rosa Coll, Olga Salamero, Ferran Vall‐Llovera, Antònia Sampol, (unknown), Marta Cervera, (unknown), Joan Bargay, Xavier Ortı́n, Josep Nomdedéu, Jordi Esteve, Jorge Sierra, (unknown)	9
7	P569: GILTERITINIB AND QUIZARTINIB IN RELAPSED/REFRACTORY (R/R) ACUTE MYELOBLASTIC LEUKEMIA (AML) WITH FLT3 MUTATIONS: A REAL-LIFE EFFECTIVENESS AND SAFETY STUDY 2022 ·HemaSphere ·(unknown), Mireia Morgades, (unknown), Marta Cervera, (unknown), Marina Díaz‐Beyá, Montserrat Arnán, (unknown), Rosa Coll, (unknown), (unknown), (unknown), Sara Mallén García, (unknown), Antònia Sampol, Jordi Esteve, David Martínez‐Cuadrón, Jorge Sierra, Miguel Á. Sanz, Josep‐María Ribera, Pau Montesinos, Susana Vives	0
8	Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1 2021 ·Blood Advances ·(unknown), Álex Bataller, Ana Garrido, Montserrat Hoyos, Montserrat Arnán, Susana Vives, Rosa Coll, Mar Tormo, Antònia Sampol, Lourdes Escoda, Olga Salamero, (unknown), Joan Bargay, (unknown), Josep Nomdedéu, Jordi Esteve, Jorge Sierra, Marta Pratcorona	19
9	Engraftment characterization of risk-stratified AML in NSGS mice 2021 ·Blood Advances ·Rafael Díaz de la Guardia, Talía Velasco-Hernández, Francisco Gutiérrez‐Agüera, Heleia Roca-Ho, Òscar Molina, César Nombela‐Arrieta, Álex Bataller, José Luís Fuster, Eduardo Anguita, Susana Vives, Lurdes Zamora, Josep Nomdedéu, María Teresa Gómez‐Casares, Manuel Ramı́rez, Hélène Lapillonne, Verónica Ramos–Mejía, Juan Carlos Rodríguez‐Manzaneque, Clara Bueno, Belén López‐Millán, Pablo Menéndez	9
10	A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients 2021 ·Annals of Hematology ·(unknown), Juan Eduardo Megías‐Vericat, Rebeca Rodríguez‐Veiga, Susana Vives, Juan Bergua, Anna Torrent, (unknown), Blanca Boluda, Joaquín Martínez‐López, (unknown), (unknown), (unknown), (unknown), (unknown), Amparo Sempere, Eva Barragán, Claudia Sargas, Miguel Á. Sanz, David Martínez‐Cuadrón, Pau Montesinos, (unknown)	10
11	A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics 2020 ·Blood Cancer Journal ·Ricardo Sánchez, Jordi Ribera, Mireia Morgades, Rosa Ayala, (unknown), (unknown), (unknown), (unknown), José María Sánchez‐Pina, Susana Vives, Lurdes Zamora, Santiago Mercadal, Rosa Coll, Marta Cervera, Olga García, Josep‐María Ribera, Joaquín Martínez‐López	12
12	Impact of previous admission to an intensive care unit on stem cell transplantation outcome 2020 ·Medicina Clínica ·(unknown), María José Jimenez, Mireia Morgades, Pilar Marcos, Pilar Ricart, Susana Vives, Blanca Xicoy, Anna Torrent, Maite Misis, (unknown), Montserrat Batlle, (unknown), Juan‐Manuel Sancho, Josep‐María Ribera, Christelle Ferrá	1
13	Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes 2017 ·Stem Cell Reports ·Rafael Díaz de la Guardia, Belén López‐Millán, Jessie R. Lavoie, Clara Bueno, Julio Castaño, María Teresa Gómez‐Casares, Susana Vives, Laura Palomo, Manel Juan, Julio Delgado, (unknown), Josep Nomdedéu, (unknown), José Luís Fuster, Eduardo Anguita, Michael Rosu‐Myles, Pablo Menéndez	75
14	Relapse risk after autologous stem cell transplantation in patients with lymphoma based on CD34+ cell dose 2016 ·Leukemia & lymphoma ·Marc Sorigué, Juan‐Manuel Sancho, Mireia Morgades, (unknown), (unknown), (unknown), Jordi Juncà, Christelle Ferrá, Montserrat Batlle, Susana Vives, (unknown), (unknown), José‐Tomás Navarro, Fuensanta Millá, Evarist Feliú, Josep‐María Ribera	4
15	Mobilization and engraftment of peripheral blood stem cells in healthy related donors >55 years old 2013 ·Cytotherapy ·(unknown), Juan‐Manuel Sancho, (unknown), Jordi Juncà, Mireia Morgades, (unknown), (unknown), Susana Vives, Montserrat Batlle, Ramón Guàrdia, Christelle Ferrá, David Gallardo, Fuensanta Millá, Evarist Feliú, Josep‐María Ribera	11
16	Predictive factors for poor peripheral blood stem cell mobilization and peak CD34+cell count to guide pre-emptive or immediate rescue mobilization. 2012 ·Cytotherapy ·Juan‐Manuel Sancho, Mireia Morgades, (unknown), Jordi Juncà, Ramón Guàrdia, Susana Vives, Christelle Ferrá, (unknown), (unknown), David Gallardo, Fuensanta Millá, Evarist Feliú, Josep‐María Ribera	40
17	Plerixafor plus G‐CSF in combination with chemotherapy for stem cell mobilization in a pediatric patient with Ewing's sarcoma 2012 ·Journal of Clinical Apheresis ·Susana Vives, Juan‐Manuel Sancho, F.M. Almazán-Fernández, Jordi Juncà, (unknown), Josep‐María Ribera	8
18	Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group 2010 ·Haematologica ·Albert Oriol, Susana Vives, Jesús María Hernández‐Rivas, Mar Tormo, (unknown), C Rivas, Concepción Bethencourt, Federico Moscardó, (unknown), Carlos Grande, Eloy del Potro, R. Guardia, Salut Brunet, Juan Bergua, Teresa Bernal, M.J. Donáte Moreno, Carlota Calvo, Pilar Bastida, Evarist Feliú, Josep‐María Ribera, (unknown)	202
19	Tratamiento de rescate y movilización de progenitores hematopoyéticos de sangre periférica con altas dosis de ifosfamida y etopósido en pacientes con linfoma 2008 ·Medicina Clínica ·Susana Vives, Juan‐Manuel Sancho, Jordi Juncà, (unknown), Mireia Morgades, Josep‐María Ribera	1
20	Enterocolitis neutropénica en adultos con leucemia aguda o receptores de un trasplante de progenitores hematopoyéticos: estudio de 7 casos 2007 ·Medicina Clínica ·Montserrat Batlle, Ferran Vall‐Llovera, Jordi Bechini, (unknown), Pilar Marcos, Susana Vives, Albert Oriol, Josep‐María Ribera	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact